RxDoctor Payments Data

Emily Meyers

Nurse Practitioner · Bethlehem, PANPI 1922496058

Payments from drug & device makers

$8,655in general payments, 2019–2025

Across 34 payments — averaging $254.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$7K
  • Medtronic$280
  • Novo Nordisk$229
  • Insulet Corporation$125
  • Bayer$125
  • Lilly USA, LLC$122
  • plus $321 from 3 others

What the payments were for

  • Speaking & faculty fees$6,28073%
  • Travel & lodging$1892%
  • Food & beverage$2,18625%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,655 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$101,903
Medicare patients
304
Services billed
2,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide142$188,068
JardianceEmpagliflozin130$129,327
MounjaroTirzepatide89$103,521
JanuviaSitagliptin Phosphate80$96,335
TrulicityDulaglutide66$79,987
Teriparatide13$43,994
FarxigaDapagliflozin Propanediol35$39,766
Tresiba Flextouch U-100Insulin Degludec47$36,239
TradjentaLinagliptin48$35,527
Humalog Kwikpen U-100Insulin Lispro141$32,380
Fiasp FlextouchInsulin Aspart (Niacinamide)40$31,382
Lantus SolostarInsulin Glargine,hum.Rec.Anlog210$30,770
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog64$30,159
Tresiba Flextouch U-200Insulin Degludec30$29,967
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog32$27,866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$229$191,315157 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$122$185,840169 claims
AstraZenecaFarxiga$95$39,76635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Bethlehem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →